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Comparative influence of body mass index on response to asthma therapy 
Abstract: Asthma in obese patients accompanies by hyperleptinemia that 
promotes systemic violations of cytokine regulation, excessive synthesis of strong 
bronchoconstrictors – cysteinyl leukotrienes. The addition of quercetin to 
budesonide combined with formoterol improves results of anti-inflammatory 
standard treatment in obese asthma patients, makes it possible to achieve asthma-
control and maintain it in the majority of patients.  
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The prevalence of both obesity and asthma have increased in recent decades. 
Several studies have shown that overweight and obesity is associated with more 
severe asthma (limitations in daily activities, breathlessness and wheezing, use of 
rescue medication, emergency department visits) and impaired quality of life, 
compared with normal weight individuals [1]. There are several mechanisms that 
may explain relationship between obesity and asthma. Obesity
 
causes airflow 
limitation, with reduction of both forced expiratory volume in one second (FEV1)
 
and forced vital capacity (FVC) [2]. Many mediators are synthesized and secreted 
by cells from adipose tissue: interleukin (IL)-6, IL-10, eotaxin, tumor necrosis 
factor (TNF)-α, C-reactive protein, leptin, adiponectin, etc. Leptin is an important 
immunoregulatory hormone
 
since it enhances a number of immune responses, 
including macrophage
 
effector functions, cytokine synthesis [4, 5], and T helper
 
(Th) cell polarization to a Th1 phenotype [6]. Thus obesity also leads to a state of 
low-grade systemic inflammation that may act on the lung to exacerbate asthma. 
Mancuso P. et al. found that leptin pretreatment
 
of either rat alveolar or 
murine peritoneal macrophages for 16 h dose dependently increased the synthesis 
of leukotriene B4 and cysteinyl leukotrienes (LT) [7]. Cysteinyl-LTs are the most 
potent endogenous bronchoconstrictors and also important regulators of 
inflammatory cytokine production, via regulation of IL-10 production and in vivo 
differentiation of T cells [8]. Cysteinyl-LT-induced activation of human monocytes 
and dendritic cells may be specifically inhibited by IL-10, suggesting a direct link 
between the 5-lipoxygenase proinflammatory pathway and IL-10 regulatory 
mechanisms [9].  
Overweight and obesity is associated with less favorable response to asthma 
therapy, with regard to symptoms, level of FEV1, fraction of exhaled nitric oxide, 
and airway responsiveness [10, 11]. Some studies suggest that asthma in the obese 
patient might be more responsive to leukotriene modifiers, than to inhaled 
corticosteroids (ICS) [12]. An alternative drug that inhibits the activity of 5-
lipoxygenase and phospholipase A2 reducing the production of LTs is 
bioflavonoid - quercetin [13]. Supressing nuclear factor-kappa (NF-κβ), which 
regulates the expression of various proinflammatory cytokines, quercetin reduces 
the production of IL-1β, TNF-α, IL-6, IL-8, IL-4, IL-13, stabilizing membranes of 
mast cells and basophils, blocking histamine out [14-18], inhibits monocyte 
chemoattractant protein synthesis by airway epithelium [19]. 
OBJECTIVES: Our aim was to assess the impact of obesity on asthma 
control, biomarkers of inflammation and response to therapy in asthma patients.  
METHODS: Achievement of asthma control as defined by the global 
initiative on asthma guidelines (GINA) was examined in 160 asthmatic patients 
using ICS. Spirometry was performed using a standard
 
spirometer. Height and 
weight were measured and body mass index (BMI)
 
was calculated. We measured 
sagittal abdominal diameter (SAD) and calculated the amount of visceral fat (AVF) 
by the formula: AVF = 0,731* SAD (cm) - 11,5. 
Inclusion criteria: Males
 
and females aged 18-60 years with a 1-yr history of 
clinical
 
symptoms of asthma with normal (BMI<25.0 kg/m
2
) weight or obesity
 
(BMI≥30.0 kg/m2). Patients' asthma treatment could include ICS at the time of 
randomization. Patients were eligible for randomization if they had
 
a FEV1>40% 
and
 
<80% of the predicted value at rest and at least a 15% increase
 
in FEV1 after ß-
agonist administration. Patients were nonsmokers. Exclusion criteria: severe 
asthma exacerbation that require systemic corticosteroid, subjects with clinically 
significant disease of any organ system that would confound the interpretation of 
the results (including diabetes mellitus).  
After examination and consideration of inclusion/exclusion criteria 132 
eligible patients with moderate to severe asthma
 
were divided into two groups 
according to their BMI. Group I: 24 normal weight patients (mean: age 42,3±2,32 
years; duration of disease 18,0±1,70 years; BMI 23.5+/-1.25 kg/m2). Group II: 108 
obese patients with mean age 47,1±0,74 years; duration of disease 16,6±0,89 years; 
BMI 34.1+/-0.34 were randomized into 2 subgroups – II-a and II-b. Number of 
patients with moderate or severe asthma were equal at each group. 
Patients of the I and II-a group received combination of inhaled budessonide 
and long-acting
 inhaled ß2-agonist – formoterol, patients of the II-b group –
budesonide in combination with formoterol and quercetin (500 mg iv for 5 days, 
then 240 mg per os daily). Patients with moderate asthma received 200 µg of 
inhaled budesonide b.i.d. and 12 µg of formoterol, patients with severe asthma 
received 400 µg of inhaled budesonide b.i.d. and 12 µg of formoterol. Treatment 
period lasted
 
3 month.
 
 
Fasting serum leptin, cysteinyl-LTs, IL-6, IL-10, TNF-α concentrations were 
measured in
 
blood serum of 80 study patients by enzyme-linked immunosorbent 
assay (ELISA).  
Statistical analysis of the results was performed according to the method of 
variation statistics using the licensed Microsoft Excel. Research values are 
presented as the sample mean, sample standard deviation. Assessment of 
differences between mean values of independent samples was performed by 
parametric method for determining the statistical significance of the difference of 
two sets of observations using the Student` and Fisher` method: calculated t value, 
was compared with tabulated values. The relations between
 
two variables were 
calculated with Spearman’s correlation test. A p value <0.05 was considered to 
indicate statistical
 
significance.
  
RESULTS: The prevalence of obesity
 
in our study's population is 36,7%.  
Obese subjects more frequently reported ß2-agonist use (4,9±0,17 vs. 
3,9±0,37, p<0,05) and nocturnal awakenings (1,8±0,08 vs. 1,3±0,13, p<0.05) in the 
previous 2 months than normal-weight subjects. In baseline airway function 
assessment we revealed that median FEV1 % pred and FVC was (59,82,10)% and 
(67,41,80)%, respectively for patients of normal weight, (55,01,01)% and  
(59,11,02)%, respectively for patients who were obese. FEV1 was negatively 
associated with BMI (r=-0,23; р<0,05), but more closely with AVF (r=-0,30, 
p<0,05). 
Asthma severity at baseline was
 
greater for obese individuals,
 
as shown by 
their lower FEV1 (% pred) and greater daily use
 of ß2-agonist.  
Presence of systemic inflammation associated with obesity with elevated 
levels of circulating mediators is shown in table 1. 
Table 1. Levels of circulating mediators in asthma patients. 
Parameter 
Groups of patients 
Control, 
n = 20 
Group І 
(with normal BMI), 
n = 22 
Subgroup ІІ-а 
(with obesity), 
n = 29 
Leptin, ng/ml  4,9 ± 0,54 14,9 ± 0,75 ٭ 35,8 ± 2,15 ٭ ٭٭  
TNF-α, pg/ml 243,2 757,31* 20411,5٭٭
*
 
IL-6, pg/ml 4,3 ± 0,31 11,3 ± 0,38٭ 24,2 ± 1,95 ٭ ٭٭  
Cysteinyl LTs, 
pg/ml 
66,8 ± 7,95 (n=12) 258,5 ± 27,58٭ 340,7 ± 26,54 ٭٭٭  
IL-10, pg/ml 4,1 ± 0,43 12,9 ± 1,28٭ 9,2 ± 1,11 ٭ ٭٭  
Notes: 
1.٭ - Statistical significance of differences (p<0,05) compared to the control; 
2.
 
٭٭ - Statistical significance of differences (p<0,05) compared with group І. 
At admission asthmatic patients with obesity had higher mean levels of 
serum leptin, TNF-α, IL-6, cysteinyl LTs than normal weight patients and vs 
control group measurements (p<0,05). IL-10 concentration was increased in both 
groups. BMI correlated significantly with leptin (r=0,78, p<0,05), TNF-α (r=0,66, 
p<0,05), IL-6 (r=0,64, p<0,05) concentrations. Leptin strongly correlated with 
TNF-α (r=0,52, p<0,05), IL-6 levels (r=0,69; p<0,05). Serum cysteinyl-LT levels 
correlated with BMI (r=0,38; p<0,05), FEV1(r=0,50; p<0,05), leptin level (r=0,35; 
p<0,05), IL-10 (r =-0,42; p<0,05).  
Thus asthma in obese patients accompanies by hyperleptinemia that 
promotes systemic violations of cytokine regulation, excessive synthesis of strong 
bronchoconstrictors – LTs. 
After budesonide-formoterol treatment for 3 month we revealed that 
nocturnal awakening and ß2-agonist use decreased to (0,2±0,08) and (0,7±0,19), 
respectively (р<0,05) in the patients of the I group vs (0,9±0,07) and (1,9±0,08), 
respectively in the patients of the II-a group (p<0,05). FEV1 and FVC increased to 
(77,71,19)% and (75,61,09)%, respectively in the patients of the I group vs 
(63,9  1,52)% and (59,8  1,20)%, respectively in the patients of the II-a group. In 
patients with asthma, serum leptin, IL-6, TNF-α, cysteinyl LTs levels were 
decreased, IL-10 was increased. Levels of circulating mediators in 3 month period 
of treatment is shown in the table 2. 
Maintenance of a high leptin, IL-6, cysteinyl LTs content after basic 
treatment with budesonide-formoterol in obese asthma patients leads to persistent 
inflammation in the bronchi explaining long-term saving of obstructive disorders 
and justifies the feasibility of the additional use of antileukotrien drugs for 
elimination of identified systemic cytokine-leukotrien imbalance. 
After 3 month of budesonide-formoterol and quercetin administration we 
revealed that nocturnal awakening and ß2-agonist use decreased to (0,3±0,08) and 
(0,9±0,09), respectively, FEV1 and FVC increased to (70,41,26) % and (62,8 
1,21) %, respectively in the patients of the II-b group and therefore contributing to 
decline obstructive disorders compared with the patients of the II-a group who 
received just budesonide-formoterol (p<0.05). 
Table 2. Levels of circulating mediators in asthma patients in 3 month period 
of treatment 
Parameter  
Groups of patients 
Control, 
n = 20 
Group І, 
n = 22 
Group ІI-a, 
n = 29 
Group ІI-b, 
n = 29 
Leptin, ng/ml 4,9 ± 0,54 9,8 ± 0,54٭ 32,3 ± 2,11٭ 32,1 ± 1,94٭** 
TNF-α, pg/ml 243,2 424,54٭ 13019,52٭ 7818,62٭*** 
IL-6, pg/ml 4,3 ± 0,31 6,8 ± 0,38٭ 17,8 ± 1,74٭ 12,3 ± 1,22٭*** 
Cysteinyl LTs, 
pg/ml 
66,8 ± 7,95  
(n=12) 
147,7±12,79٭ 268,8±18,91٭ 187,0±23,4٭*** 
IL-10, pg/ml 4,1 ± 0,43 22,2 ± 1,87٭ 16,5 ± 1,49٭ 20,8 ± 1,45٭*** 
Notes: 
1.٭ - Statistical significance of differences (p<0.05) compared to the control; 
2.
 
٭٭ - Statistical significance of differences (p<0.05) compared with group І; 
3. * - Statistical significance of differences (p<0.05) compared with group 
IІ-a. 
The addition of quercetin to budesonide-formoterol was statistically superior 
to budesonide-formoterol for obese subjects for ß2-agonist use, FEV1 (p<0,05), 
levels of pro- and anti-inflammatory mediators, except leptin concentrations (p< 
0,05). The addition of quercetin makes it possible to improve results of anti-
inflammatory standard treatment in obese asthma patients. 
Of patients with normal weight, (58,3±10,3)% achieved asthma-control 
compared with (9,2±3,9)% of patients who were obese (p<0,05). Of obese patients, 
(24,1±5,8)% achieved asthma-control after 3 month of budesonide-formoterol with 
quercetin treatment compared with (9,2±3,9)% of patients who were used just 
budesonide-formoterol inhalations (p<0,05). Partly controlled asthma was revealed 
in (41,7±10,3)% of normal weight patients, (63,0±6,6)% of patients of the II-a 
group and (64,8±6,6)% - of the II-b group (p>0,05). Asthma course remained 
uncontrolled in (27,8±6,2)% of patients from the II-a group and (11,1±4,3)% - of 
the II-b group (p<0,05). 
CONCLUSIONs: Obesity is associated with poorer asthma control: obese 
asthma patients demonstrated more usage of ß2-agonists and more significant 
obstructive disturbances in lung function.  
Persistent hyperleptinemia in obese asthma patients contributes to increased 
synthesis of cysteinyl-LTs, IL-6, TNF-α, reduced production of IL-10, and as a 
result – reduced response to ICS. 
The influence of BMI on response to combined treatment with quercetin was 
different from that observed for budesonide-formoterol: treatment in combination 
with quercetin resulted in
 
improvement in asthma control in obese individuals due 
to significant reduction in serum cysteinyl-LTs, IL-6, TNF-α, and increase in 
serum IL-10.  
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